clinical trial · NCT03112603
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Graft-versus-host Disease (GVHD)RuxolitinibExtracorporeal photopheresis (ECP)Low-dose methotrexate (MTX)Mycophenolate mofetil (MMF)mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)InfliximabRituximabPentostatin
brief summary
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
started
Jun 29, 2017
primary completion
May 8, 2020
completion
Dec 15, 2022
last updated
Aug 12, 2025
official title
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol